Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arginine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Arginine. Displaying page 7 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-003309-88 Sponsor Protocol Number: ROR-PH-302 Start Date*: 2020-06-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He...
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004946-41 Sponsor Protocol Number: SP-PP18 Start Date*: 2019-09-12
    Sponsor Name:Dr. Virgilio P. Carnielli,
    Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial
    Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005242-23 Sponsor Protocol Number: NV-NEGRIN-2008-001 Start Date*: 2009-03-31
    Sponsor Name:Nicanor Vega Diaz. Hospital Universitario de Gran Canaria Dr Negrin
    Full Title: ESTUDIO UNICENTRICO, PROSPECTIVO Y ALEATORIZADO DE COMPARACION DE LOS EFECTOS DE DIFERENTES SOLUCIONES DE DIALISIS PERITONEAL SOBRE LA FUNCIONALIDAD DE LA MEMBRANA PERITONEAL EN PACIENTES INCIDE...
    Medical condition: Cambios funcionales de la membrana peritoneal en los pacientes en diálisis peritoneal automatizada que sean asignado a dianeal o physioneal
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2015-002116-32 Sponsor Protocol Number: MTM-04 Start Date*: 2015-09-23
    Sponsor Name:Køge Hospital
    Full Title: The effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep disturbances in patients after acute myocardial syndrome
    Medical condition: Depression Anxiety Sleep disturbances Circadian disturbances
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009190 Circadian dysrhythmia LLT
    19.0 100000004873 10002865 Anxiety reaction LLT
    19.0 100000004873 10040999 Sleep disturbed LLT
    19.0 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000166-37 Sponsor Protocol Number: AIR001-CS05 Start Date*: 2013-01-22
    Sponsor Name:Aires Pharmaceuticals Inc
    Full Title: A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005992-81 Sponsor Protocol Number: CL-N-CSM-III/01/08 Start Date*: 2011-03-21
    Sponsor Name:Dr. F. Köhler Chemie GmbH
    Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol
    Medical condition: The study population will be selected from both genders with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery. The ratio of incidence for b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001045-14 Sponsor Protocol Number: SAF001 Start Date*: 2013-04-22
    Sponsor Name:Promethera Biosciences
    Full Title: SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem.
    Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000933-18 Sponsor Protocol Number: HLSC-UCD-02 Start Date*: Information not available in EudraCT
    Sponsor Name:Unicyte AG
    Full Title: An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Ure...
    Medical condition: Urea cycle disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000610-10 Sponsor Protocol Number: RivAsA Start Date*: 2020-01-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s...
    Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10067825 Peripheral arterial disease LLT
    21.0 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003361-37 Sponsor Protocol Number: C5041005 Start Date*: 2023-03-06
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRI...
    Medical condition: Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023430-23 Sponsor Protocol Number: EMR701048_009 Start Date*: 2011-01-17
    Sponsor Name:Merck Serono S.A.
    Full Title: A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (Saizen solution for injection) when administered to male and female a...
    Medical condition: This is GH replacement therapy in adult subjects with documented Growth Hormone Deficiency (GHD) either idiopathic or acquired and childhood- or adult-onset
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004793-17 Sponsor Protocol Number: 402-C-1302 Start Date*: 2017-05-03
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
    Medical condition: Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017595-25 Sponsor Protocol Number: 04-AnIt-09/UKM09_0031 Start Date*: 2011-02-22
    Sponsor Name:University Hospital Muenster
    Full Title: Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery
    Medical condition: Patients undergoing colorectal surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10040668 Sigmoid hemicolectomy LLT
    14.1 10042613 - Surgical and medical procedures 10009879 Colectomy total PT
    14.1 10042613 - Surgical and medical procedures 10059848 Proctocolectomy PT
    14.1 10042613 - Surgical and medical procedures 10009877 Colectomy NOS LLT
    14.1 10042613 - Surgical and medical procedures 10019460 Hemicolectomy LLT
    14.1 10042613 - Surgical and medical procedures 10039153 Right hemicolectomy LLT
    14.1 10042613 - Surgical and medical procedures 10024107 Left hemicolectomy LLT
    14.1 10042613 - Surgical and medical procedures 10063950 Ileocolectomy PT
    14.1 10042613 - Surgical and medical procedures 10061778 Colectomy PT
    14.1 10042613 - Surgical and medical procedures 10044083 Total colectomy LLT
    14.1 10042613 - Surgical and medical procedures 10009878 Colectomy partial LLT
    14.1 10042613 - Surgical and medical procedures 10063065 Anterior rectum resection LLT
    14.1 10042613 - Surgical and medical procedures 10009880 Colectomy transverse LLT
    14.1 10042613 - Surgical and medical procedures 10033684 Panproctocolectomy LLT
    14.1 10042613 - Surgical and medical procedures 10044447 Transverse colectomy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000302-12 Sponsor Protocol Number: BUC-CLIN-303 Start Date*: 2016-07-13
    Sponsor Name:ARCA biopharma, Inc.
    Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000685-15 Sponsor Protocol Number: AXA1125-101 Start Date*: 2021-10-18
    Sponsor Name:Axcella Health, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi...
    Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000239-34 Sponsor Protocol Number: PONTIACII Start Date*: 2015-12-30
    Sponsor Name:Medizinische Universität Wien
    Full Title: NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
    Medical condition: The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006184-19 Sponsor Protocol Number: SPI-62-CL-2001 Start Date*: 2022-06-22
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10014698 - Endocrine disorders 10035109 Pituitary-dependent Cushing's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003989-27 Sponsor Protocol Number: PROLONGSTEM Start Date*: Information not available in EudraCT
    Sponsor Name:Promethera Therapeutics
    Full Title: PROLONGSTEM: HepaStem Long-Term Safety Registry Registry for patients who have been administered HepaStem
    Medical condition: This study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    21.1 200000003094 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 18:47:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA